The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.’s Omvoh, a new therapy to treat Chron’s disease and ulcerative colitis, is the company’s latest step into the treatment of gastrointestinal diseases.
Pete Yonkman, president of Cook Group and Cook Medical, was among the speakers Monday at the official launch of the new Indiana University IU Launch Accelerator for Biosciences, or IU LAB.
Syra Health is looking to its new AI-powered app, Syrenity, to help it reach profitability and establish itself as a provider of high-tech mental health services.
The health care company has expanded its reach over the past seven years to become a master developer for a sprawling project on the south side of Interstate 70 in western Hancock County.
AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially helping Eli Lilly and Co. and other companies develop new medicines more quickly.
Kristin Sherman leads startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human papillomavirus infections before cancer develops and to treat HPV cancers after detection.
Lilly’s stock was up slightly in after-hours trading.
After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ride since September.
After 10 long years, the company that has developed a collagen biomaterial to help heal tissue is readying itself for its next big steps: regulatory approval and commercial launch.
The economics are daunting: Rising costs and flat reimbursements mean private groups must work harder to stay independent.
Ricks is being recognized for his contributions to Indiana’s life sciences sector and his global impact on health care innovation.
But two years after the groundbreaking for an Ascension St. Vincent facility in West Lafayette, the planned $25 million development has little to show for itself. The 7-acre site sits empty, with no indication that anything is coming soon.
In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And modes of drug delivery are becoming increasingly complex.
In response, an Indianapolis medical practice is trying to train more early-career physicians in the field of hematology to reverse the trend of dwindling numbers of physicians entering the field.
Indiana physicians are keeping an eye on the trend of large insurers dropping medical practices from their networks, which they call a classic case of David versus Goliath.
The five-year-old company is developing treatments for endocrine and metabolic disorders, such as hypoparathyroidism, post-bariatric hypoglycemia and obesity. Its positive reception on Wall Street was seen as an extension of the general enthusiasm for obesity treatments.
Lucas Montarce, who has been with Lilly since 2001 and most recently served as president for its Spain, Portugal and Greece operations, is now the company’s CFO and executive vice president.
Economic development leaders want the 45 acres to be developed as the OneHealth Innovation District—a partnership between Elanco Animal Health, Purdue University and the Indiana Economic Development Corp.
Fishers-based Flexware Integration LLC, a fast-growing IT services provider, has acquired Castle Hill Technologies LLC, a North Carolina-based company that provides engineering services to the pharmaceutical industry.
A national proposal to remove medical debt from consumer credit reports could have a significant impact in Indiana, where the percentage of residents with delinquent medical debt is higher than in 39 other states.
